Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

193.41 15.76 +8.87%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a

Revolution Medicines, Inc. (RVMD) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Revolution Medicines, Inc. (RVMD) trades at a EV/FCF of −25.0×. Over the past ten years it has ranged from −35.5× (August 2026) to 1.5× (March 2020); the current reading is higher than 10% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2023 −6.1× —
FY2022 −5.4× —
FY2021 −8.6× —
FY2020 −17.1× —
FY2019 0.9× 0.00%
FY2018 0.9× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 −28.8× —
Dec 2023 −6.1× —
Jun 2023 −8.0× —
Mar 2023 −5.0× —
16 more quarters

Against its own ten years

Low −35.5× High 1.5×
Ten-year median −9.7×
Current reading's percentile 10

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on RVMD